pH-Dependent Fatty Acid Carriers for Targeted NSAID Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations for delivering non-steroidal anti-inflammatory drugs (NSAIDs) lack the ability to target the release of these agents specifically to different parts of the gastrointestinal (GI) tract, leading to gastrointestinal toxicity and inefficiencies in drug delivery, as they are often injurious to the upper GI tract and subject to first-pass metabolism.
Innovation Solution
A pharmaceutical composition comprising a solid, biologically active NSAID suspended in a non-aqueous liquid carrier with greater than 14 wt.% of a free fatty acid and less than 10 wt.% of phospholipid, which releases the agent in a pH-sensitive manner, allowing minimal release in low pH environments like the stomach and efficient release in higher pH environments like the duodenum and small intestine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are administered in conventional formulations, then anti-inflammatory efficacy is achieved, but gastrointestinal toxicity occurs due to release in the upper GI tract
Solution Approach 1:
The patent applies preliminary action by pre-formulating NSAIDs in a carrier system containing free fatty acids and phospholipids that will remain stable and retain the drug in the stomach, then automatically release it at the target site (duodenum/small intestine) when pH conditions change. This preliminary preparation ensures the drug reaches its destination before becoming active, preventing premature GI tract exposure while maintaining therapeutic efficacy.
2Productivity
If NSAIDs are released in the stomach for rapid absorption, then bioavailability increases, but GI mucosal injury is exacerbated
Solution Approach 1:
The patent uses free fatty acids and phospholipids as intermediary substances that mediate between the NSAID and the GI tract. These intermediaries form a protective carrier system that prevents direct contact between the NSAID and gastric mucosa, while still enabling controlled drug release. The intermediaries facilitate targeted delivery to the duodenum where they aid in drug solubility and absorption without causing mucosal damage.
3Ease of operation
If conventional NSAID formulations are used, then ease of administration is maintained, but first-pass metabolism reduces therapeutic effectiveness
Solution Approach 1:
The patent applies preliminary action by designing a pH-dependent release system that pre-plans the drug's release location. The carrier system is formulated in advance to remain stable through the stomach and only release the NSAID in the duodenum/small intestine where pH conditions trigger dissociation. This preliminary positioning bypasses first-pass metabolism by ensuring the drug is released after gastric emptying, maintaining both ease of oral administration and enhanced therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This composition effectively reduces gastrointestinal toxicity by minimizing NSAID release in the stomach and maximizing it in the small intestine, enhancing bioavailability and reducing adverse effects, while also being suitable for other pharmaceutical and nutraceutical agents.
Implementation Method 1
releases the agent in a pH-sensitive manner, allowing minimal release in low pH environments like the stomach and efficient release in higher pH environments like the duodenum and small intestine
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.